Replies to post #212346 on Biotech Values

[DewDiligence]

…at this level Revance is fairly priced. I base this on the thought that they'll follow the current "dilute on news" theory, which will happen shortly.

Agree that RVNC will likely raise capital this year (#msg-131213039), but that doesn’t imply that the stock is fully valued.

Moreover, an opportunistic financing might even cause the share price to rise, a pattern recently seen with several biotech companies.